• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MediciNova, Inc. - Common Stock (NQ:MNOV)

    1.671 -0.009 (-0.52%)
    Streaming Delayed Price Updated: 1:26 PM EST, Jan 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about MediciNova, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    2026 New Year’s Greetings from the CEO
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ ↗
    Via Stocktwits
    News headline image
    Message from the CEO to MediciNova Shareholders
    Strengthening MN-001’s Scientific Foundation and Clinical Outlook 
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    Unusual volume stocks in Monday's session ↗
    In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Friday? ↗
    Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
    Via Chartmill
    News headline image
    These stocks have an unusual volume in today's session ↗
    In today's session, these stocks are experiencing unusual volume. 
    Via Chartmill
    News headline image
    Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? ↗
    MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research. 
    Via Benzinga
    News headline image
    MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
    Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients 
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova to Present at the LD Micro Main Event XIX Investor Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
    ~Patient Recruitment Closed~ 
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Provides Shareholder Update on Key Developments
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
    MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients 
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
     
    Via Benzinga
    News headline image
    MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
    NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy 
    From MediciNova, Inc.
    Via GlobeNewswire
    News headline image
    MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
    From MediciNova, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.